China channel feed – Endpoints News

China channel feed

Back again: Merck willing to dole out more than $9B for Kelun’s ADCs

3 years ago

Legend CEO spells out path to $5B in sales for multiple myeloma CAR-T therapy Carvykti

3 years ago

CFIUS review triggers delay on F-star's sale to Chinese player

3 years ago

China bans GSK from drug procurement activities through April 2024

3 years ago

After $10B in market value lost, China's WuXi Biologics removed from US unverified list

3 years ago

Moderna refused to disclose mRNA vaccine technology to China — report

3 years ago

China’s YishengBio is going to Nasdaq, making the transition via $230M SPAC maneuver

3 years ago

Almirall partners up with Simcere in potential $500M+ deal — with plans to take IL-2 candidate global

3 years ago

Biden directive on screening foreign investments in US biotech not targeted at China, admin officials say

3 years ago

#ESMO22: Dizal touts win in niche NSCLC population cornered by Takeda, J&J

3 years ago

Shanghai-based cell therapy biotech nabs new funds; Colorado biotech nets an acquisition

3 years ago

China's DNA giant confronts skepticism in US expansion bid

3 years ago

US and China develop framework for inspection of 200 US-listed companies under threat of delisting

3 years ago

ICYMI: James Sabry just signed off on a landmark first for Roche's dealmaking crew

3 years ago

Roche, Genentech plunk down $60M upfront to partner with Chinese pharma on PROTAC-based prostate cancer drug

3 years ago

BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-related biotech, with ARCH jumping in

3 years ago

Merck's ADC hunt continues with second deal for China biotech Kelun

3 years ago

Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks

3 years ago

Scoop: AbbVie terminates early-stage study of I-Mab's antibody, another clinical setback in CD47 field

3 years ago

Novartis’ $650M cash bet on a near-term FDA OK for BeiGene’s China PD-1? It just got delayed indefinitely

3 years ago

Sinopharm mulls $1B buyout of China-based DNA synthesis company — report

3 years ago

Legend scraps trial of its follow-up autologous CAR-T weeks after clinical hold was lifted

3 years ago

Two months after CRL, FDA accepts Coherus, Junshi's resubmission for PD-1 studied in China

3 years ago

With Lilly's backing, a CRO with roots in China bags $150M round to fuel global growth

3 years ago

First page Previous page 8 9 101112 13 14 Next page Last page